Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Low what is your next stock of interest when Oncosec inevitably gets bought out after they reveal positive PISCES data? Just curious. I like to build on my watchlist of interesting stocks. Good luck to you.
Christmas is gonna come early this year to Oncosec shareholders. Oh yeah, and AH buys....price bounced nicely of the recentl pullback....price currently...1.95
Only a matter of time before Oncosec gets swooped up by Big Pharma!
lol...alot of things are worthless in this world....but a positive opinion on Oncosec, a company making great strides to bring a new cancer immunotherapy platform to the market is not one of them. Oppenheimer coverage announcement likely this week, followed by positive market reaction to TNBC news from AACR in the following weeks will have Oncosec primed for a major move higher when PISCES data is released in a few more months. Good luck to all Oncosec shareholders! Those not in favor of Oncosec, good luck to you too, make love not war.
Oh, there is definitely a comparison...keep an eye out for Oppenheimer coverage of Oncosec soon.
Well, Merck just did a takeover of Viralytics which also had a collaboration with BMY. Bristol Myers might be more inclined now to swoop in and pick up Oncosec out from under Merck in this continuing battle between the two giant companies to pick up small promising biotech.
Ahab, I am fully confident that this is Oncosec's year to shine. Tutes are loading. I am sure the next quarters sec filings will show many more stakes taken here. Oppenheimer was the sales agent for the fall ATM that was cancelled and Oncosec presenting at their conference certainly leads me to believe we will see coverage initiated soon with a decent target. OPPY has has ONCS on the radar.
The sudden development with TNBC makes Oncosec a bit more interesting. AACR data and special meeting afterwards should shed light on things going forward. If BMY enters the picture now for a TNBC phase II combo partnership with upfront money and exclusive licensing deal in that indication...a bidding war with Merck seems likely. TNBC would probably follow the same path as current PISCES trial with fast track and orphan drug indications. $20 buyout price would be very reasonable. Good PISCES data as well as TNBC confirmation data will lead to the start of the planned IST trials and what you have here is a blossoming Oncosec primed for the buyout.
No, Merck is not the buyer spiking volume today...simply pointing out the stock movement prior to their buyout of Viralytics recently. Somebody obviously knew it was coming. Now we have serious volume in Oncosec after Oppenheimer conference. Interest is spiking now in anticipation of data and possible partnering. Day traders are taking their profits, share price will be moving back higher very soon...bank on it. I wouldn't be surprised if monday morning we see Oppenheimer come out with Oncosec coverage and a nice price target.
Don't be fooled. Merck recently bought out Viralytics...which spike 14 mil shares and closed flat, had some down days...and then...boom buyout announced
Intense loading at 1.83
my guess...Oppenheimer initiating coverage on Oncosec with a nice price target.
That day might be on the horizon....and the stock price just might be higher than $20.
29,366 more shares bought after Hours too.
gee...did you really think I was serious? Only a fool would sell Oncosec in 2018. Too many catalysts this year.
nah....just kidding. I think I will sell after PISCES positive data rockets Oncosec shares much higher. It is coming. Data probably at ASCO in June.
Oh crap...you are right...it’s really no big deal at all...I’ll sell.
Proof is in the pudding
Oh...okay...got it
I see the light now. I should buy a Big Mac instead
You know...Kevin
How about abc?
Yeah, I guess you are right...I’ll sell
Well if BMY doesn't have an interest in Oncosec for TNBC I am sure Merck will. Merck and Bristol Myers will continue to duke it out. On good PISCES data Merck will probably just buy them out and expand the Oncosec pipeline into many more indications to rival Bristol Myers. The future of Oncosec tech looks very compelling to any suitor in my opinion.
I totally agree current price targets are low. Good PISCES results and we will see immediate targets raised and probably more prominent coverage. Easily above $10 this year if PISCES gets good results and fast tracked.
Dr. Kevin Hollevoet (KU Leuven) is now Advisor of Biomedical R&D at OncoSec Medical. He presented at 2nd Next Gen Oncology Congress yesterday. Expecting update on KU Leuven and Oncosec collaboration.
Oncosec has added an additional PISCES recruitment site. That makes 10 sites total now. Anticipation should be growing for interim results mid-year 2018.
Oncosec pilot TNBC trial was slow to enroll, then trial was expanded by treating 2 heavily pre-treated TNBC patients..now with Opdivo + Oncosec therapy. Both patients had robust response. Either Oncosec got very lucky picking those 2 patients or COMBO works EXCELLENT!
Maxim report on Oncosec out today. Price target still $5. They are expecting data on the first 15 patients in PISCES trial this summer. Oncosec cash stands at $35 million with a runway into 2019.
oh, sure there is...FDA granted Oncosec fast-track designation for melanoma.
Seems very likely that Oncosec will announce a drug supply agreement similar to the Merck agreement for PISCES to start a PhaseII TNBC trial. Oncosec already raised 23 mil to sponsor the TNBC trial themselves. I expect Bristol Myers to be the drug supply partner since the two patients in the pilot study who had robust responses were dosed with Opdivo....seems obviou.
PISCES data as well as TNBC data at AACR will surely be a big deal for Oncosec this year. PISCES data will be most important. If you didn't know yet, BORR of 30% will get Oncosec PISCES trial fast tracked for approval in 2019.
Oncosec and KU Leuven both speaking at 2nd Annual Next Gen Immuno-Oncology Congress to be held on 13th and 14th March 2018. Any bets that we might hear some news of the collaboration started in 2016.
I don't believe the CEO of Oncosec is lying to Oncosec shareholders. He said that the 23 mil equity raise was to sponsor a TNBC combination phase II trial with checkpoint therapy. 2 patients of the 5 in the pilot study were given Opdivo as following treatment so it is likely the collaboration in a phase II trial will be with Bristol Myers. Good times are ahead for Oncosec and shareholders. Good luck to you and all holders of Oncosec shares. Looking great this year. I am very excited.
If you listen to the recent webcast from the LD Micro conference, Oncosec's CEO, Dan O'Connor, absolutely said the recent equity raise for 23 mil was to support (sponsor) a TNBC phase II trial in combination with checkpoint therapy....based on their pilot TNBC study at Stanford.
Yes, it seems obvious that the TNBC Pilot study yielded very compelling data for Oncosec to do a quick 23 mil equity raise to get a phaseII TNBC trial under way. I would think the collaborator would obviously be Bristol Myers since the two patients were dosed with Opdivo. Looking forward to abstracts released for AARC next week, then we will know for sure if Oncosec is presenting the detailed data there next month.
I agree Jeff. We are in good shape right now awaiting partnership news and data from PISCES. Well funded now....looking good.
Thanks Jeff. I think the info regarding TNBC is the boost we needed here. I also like that O'Connor electroporated himself to see what the pain threshold was....and it was minimal. I like that he did that. Looking good today for a move up.
Oncosec had a nice close today Jeff. Do you think we are now breaking out of the cup and handle chart pattern? How high do you think we can move on a technical basis before TNBC or PISCES data hits? Nice to see the move higher this week.